退形成性星細胞腫の世界市場レポート 2025年

退形成性星細胞腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.0％で6億2,000万米ドルに成長します。予測期間の成長は、研究開発活動の増加、個別化医療に対する需要の高まり、投資の増加、疾患に対する意識の高まり、ストレスやうつ病の増加などに起因すると考えられます。予測期間の主な動向としては、神経外科手術の進歩、放射線治療の進歩、臨床試験と研究、遠隔医療と遠隔モニタリング技術の採用、画像診断の進歩、バイオテクノロジーと医薬品開発などが挙げられます。

退形成性星細胞腫市場は、原発性悪性脳腫瘍と非悪性脳腫瘍の両方の発生が増加していることから成長が見込まれています。脳腫瘍は脳内の異常増殖であり、がん性（悪性）で浸潤性のものと、非がん性（良性）で非浸潤性のものに分類され、その悪性度や広がる可能性はさまざまです。退形成性星細胞腫治療には、脳機能を温存しながら腫瘍とその周囲の罹患組織を除去することが含まれます。例えば、米国を拠点とする非営利団体である米国臨床腫瘍学会（ASCO）の報告によると、2023年3月に米国で原発性脳腫瘍および脊髄腫瘍の診断を受ける成人は約24,810人で、男性が14,280人、女性が10,530人と推定されています。その結果、原発性悪性脳腫瘍および非悪性脳腫瘍の罹患率の上昇が、今後の退形成性星細胞腫市場の成長促進要因になると予測されます。

退形成性星細胞腫市場の成長が期待されるのは、脳腫瘍研究のための政府助成金です。政府資金とは、さまざまなレベル（連邦、州、地方）の政府機関が組織、イニシアチブ、プロジェクト、プログラム、または個人を支援するために提供する財政支援を含みます。数多くの政府当局が、退形成性星細胞腫を含む脳腫瘍治療に関連する研究に積極的に資金を提供しています。例えば、2023年6月、オーストラリア保健・高齢者医療省は、脳腫瘍研究を支援するために1億3,666万米ドルを割り当て、「オーストラリア脳腫瘍ミッション」を開始しました。このミッションは、退形成性星細胞腫の患者を含む脳腫瘍患者の生存率を倍増させ、生活の質を向上させることを目的としています。その結果、脳腫瘍研究に対する政府の資金援助が退形成性星細胞腫市場の主要な促進要因となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界退形成性星細胞腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の退形成性星細胞腫市場：成長率分析
• 世界の退形成性星細胞腫市場の実績：規模と成長, 2019-2024
• 世界の退形成性星細胞腫市場の予測：規模と成長, 2024-2029, 2034F
• 世界退形成性星細胞腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の退形成性星細胞腫市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• グレードI
• グレード II
• グレードIII
• グレードIV
• 世界の退形成性星細胞腫市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 手術
• 化学療法
• 放射線
• 世界の退形成性星細胞腫市場治療段階別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 事前登録フェーズ
• 臨床試験段階
• 世界の退形成性星細胞腫市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 小売薬局
• オンライン薬局
• 世界の退形成性星細胞腫市場、グレードIのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 毛様細胞性星細胞腫
• 世界の退形成性星細胞腫市場、グレード IIのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• びまん性星細胞腫
• 乏突起膠腫
• 世界の退形成性星細胞腫市場、グレードIIIのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 退形成性星細胞腫
• 未分化乏突起膠腫
• 世界の退形成性星細胞腫市場、グレードIVのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 多形性膠芽腫（GBM）
• 原発性神経膠芽腫
• 二次性神経膠芽腫

第7章 地域別・国別分析

• 世界の退形成性星細胞腫市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の退形成性星細胞腫市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 退形成性星細胞腫市場：競合情勢
• 退形成性星細胞腫市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Eisai Co. Ltd
• Boehringer Ingelheim International GmbH
• Perrigo Company Plc
• Ipsen SA
• Genentech Inc
• Cipla Limited
• Novocure Ltd.
• Celon Laboratories Limited
• Avid Bioservices Inc.
• EirGen Pharma Ltd.
• Monteris Medical Corporation
• GLS Pharma Pvt. Ltd.
• Tocagen Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 退形成性星細胞腫市場2029：新たな機会を提供する国
• 退形成性星細胞腫市場2029：新たな機会を提供するセグメント
• 退形成性星細胞腫市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Anaplastic astrocytoma is a rare and malignant brain tumor that originates from astrocytes, which are the supportive cells in the nervous system. This condition can lead to neurological symptoms such as headaches, seizures, behavioral changes, and motor deficits, and is typically managed through a combination of surgical procedures, radiation therapy, and chemotherapy.

Anaplastic astrocytoma is categorized into four main grades such as Grade I, Grade II, Grade III, and Grade IV. Grade I anaplastic astrocytoma tumors are the least aggressive and considered benign. They are typically treated with surgical excision, routine monitoring, and follow-up procedures. Treatment options for anaplastic astrocytoma also include surgery, chemotherapy, and radiation, which are further classified into pre-registration and clinical trial phases. These treatments are administered by medical facilities such as hospitals and clinics, and the medications can be obtained from retail pharmacies and online pharmacies.

The anaplastic astrocytoma market research report is one of a series of new reports from The Business Research Company that provides anaplastic astrocytoma market statistics, including anaplastic astrocytoma industry global market size, regional shares, competitors with an anaplastic astrocytoma market share, detailed anaplastic astrocytoma market segments, market trends and opportunities and any further data you may need to thrive in the anaplastic astrocytoma industry. This anaplastic astrocytoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anaplastic astrocytoma market size has grown strongly in recent years. It will grow from $0.44 billion in 2024 to $0.47 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to growing adoption of targeted therapies, patient advocacy and awareness, clinical trial expansion, healthcare policy and funding, government initiatives.

The anaplastic astrocytoma market size is expected to see strong growth in the next few years. It will grow to $0.62 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing research and development activities, growing demand for personalized medicine, growing investments, increasing awareness of the disease, increasing stress and depression. Major trends in the forecast period include advancements in neurosurgery, radiation therapy advancements, clinical trials and research, adoption of telemedicine and remote monitoring technologies, advancements in imaging, biotechnology and drug development.

The anaplastic astrocytoma market is anticipated to experience growth due to the increasing occurrence of both primary malignant and non-malignant brain tumors. Brain tumors are abnormal growths within the brain that can be categorized as either cancerous (malignant) and invasive or non-cancerous (benign) and non-invasive, with varying levels of aggressiveness and potential to spread. Anaplastic astrocytoma treatment involves the removal of the tumor and surrounding affected tissue while preserving brain function. For instance, as reported by the American Society of Clinical Oncology (ASCO), a non-profit organization based in the United States, it is estimated that around 24,810 adults in the U.S. will receive diagnoses of primary cancerous brain and spinal cord tumors in March 2023, with 14,280 cases in men and 10,530 in women. Consequently, the rising incidence of primary malignant and non-malignant brain tumors is poised to be a driving factor for the growth of the anaplastic astrocytoma market in the future.

The anticipated growth in the anaplastic astrocytoma market is expected to be driven by government funding for brain cancer research. Government funding involves financial support provided by government entities at various levels (federal, state, or local) to support organizations, initiatives, projects, programs, or individuals. Numerous government authorities are actively funding research related to brain cancer treatments, including anaplastic astrocytoma. For example, in June 2023, the Australian Department of Health and Aged Care initiated The Australian Brain Cancer Mission, allocating $136.66 million to support brain cancer research. The mission aims to double survival rates and enhance the quality of life for brain cancer patients, including those with anaplastic astrocytoma. As a result, government funding for brain cancer research is a key driver for the anaplastic astrocytoma market.

Prominent companies in the anaplastic astrocytoma market are actively engaged in pioneering novel treatment options with the aim of enhancing effectiveness, reducing side effects, and ultimately improving patient outcomes. For example, in June 2022, the U.S. Food and Drug Administration, a federal agency based in the United States, granted accelerated approval for an innovative treatment combination featuring the oral medications dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors characterized by the BRAF V600E mutation. This approval applies to both adult and pediatric patients with high- and low-grade gliomas that have shown progression following prior treatments. The BRAF V600E mutation is prevalent in various types of gliomas, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas. The decision to grant approval was based on clinical trials of the Tafinlar-Mekinist combination therapy, which demonstrated tumor shrinkage benefits for both adult and pediatric glioma patients. High-grade glioma patients exhibited a 33% response rate, low-grade glioma patients showed a 50% response rate, and pediatric glioma patients demonstrated a 25% response rate.

Major companies operating in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Perrigo Company PLC, Ipsen SA, Genentech Inc., Cipla Limited, Novocure Ltd., Celon Laboratories Limited, Avid Bioservices Inc., EirGen Pharma Ltd., Monteris Medical Corporation, GLS Pharma Pvt. Ltd., Tocagen Inc., Pharma's Almanac, Inovio Pharmaceuticals Inc., Isarna Therapeutics GmbH, Actiza Pharmaceutical Private Limited, Celldex Therapeutics Inc.

North America was the largest region in the anaplastic astrocytoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anaplastic astrocytoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the anaplastic astrocytoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anaplastic astrocytoma market consists of revenues earned by entities by providing targeted therapies, genetic testing and biomarker analysis, clinical trials and healthcare services. The market value includes the value of related goods sold by the service provider or included within the service offering. The anaplastic astrocytoma market also includes sales of surgical equipment, imaging devices and radiation therapy equipment that are used in providing anaplastic astrocytoma treatment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anaplastic Astrocytoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anaplastic astrocytoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anaplastic astrocytoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anaplastic astrocytoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Grade I; Grade II; Grade III; Grade IV
• 2) By Treatment Type: Surgery; Chemotherapy; Radiation
• 3) By Treatment Phase: Pre-Registration Phase; Clinical Trial Phase
• 4) By End-User: Hospitals And Clinics; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Grade I: Pilocytic Astrocytoma
• 2) By Grade II: Diffuse Astrocytoma; Oligodendroglioma
• 3) By Grade III: Anaplastic Astrocytoma; Anaplastic Oligodendroglioma
• 4) By Grade IV: Glioblastoma Multiforme (GBM); Primary Glioblastoma; Secondary Glioblastoma
• Companies Mentioned: Pfizer Inc.; Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Anaplastic Astrocytoma Market Characteristics

3. Anaplastic Astrocytoma Market Trends And Strategies

4. Anaplastic Astrocytoma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Anaplastic Astrocytoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Anaplastic Astrocytoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Anaplastic Astrocytoma Market Growth Rate Analysis
• 5.4. Global Anaplastic Astrocytoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Anaplastic Astrocytoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Anaplastic Astrocytoma Total Addressable Market (TAM)

6. Anaplastic Astrocytoma Market Segmentation

• 6.1. Global Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Grade I
• Grade II
• Grade III
• Grade IV
• 6.2. Global Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Chemotherapy
• Radiation
• 6.3. Global Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pre-Registration Phase
• Clinical Trial Phase
• 6.4. Global Anaplastic Astrocytoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Retail Pharmacy
• Online Pharmacy
• 6.5. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pilocytic Astrocytoma
• 6.6. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade II, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diffuse Astrocytoma
• Oligodendroglioma
• 6.7. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade III, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Anaplastic Astrocytoma
• Anaplastic Oligodendroglioma
• 6.8. Global Anaplastic Astrocytoma Market, Sub-Segmentation Of Grade IV, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glioblastoma Multiforme (GBM)
• Primary Glioblastoma
• Secondary Glioblastoma

7. Anaplastic Astrocytoma Market Regional And Country Analysis

• 7.1. Global Anaplastic Astrocytoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Anaplastic Astrocytoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anaplastic Astrocytoma Market

• 8.1. Asia-Pacific Anaplastic Astrocytoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anaplastic Astrocytoma Market

• 9.1. China Anaplastic Astrocytoma Market Overview
• 9.2. China Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anaplastic Astrocytoma Market

• 10.1. India Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anaplastic Astrocytoma Market

• 11.1. Japan Anaplastic Astrocytoma Market Overview
• 11.2. Japan Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anaplastic Astrocytoma Market

• 12.1. Australia Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anaplastic Astrocytoma Market

• 13.1. Indonesia Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anaplastic Astrocytoma Market

• 14.1. South Korea Anaplastic Astrocytoma Market Overview
• 14.2. South Korea Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anaplastic Astrocytoma Market

• 15.1. Western Europe Anaplastic Astrocytoma Market Overview
• 15.2. Western Europe Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anaplastic Astrocytoma Market

• 16.1. UK Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anaplastic Astrocytoma Market

• 17.1. Germany Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anaplastic Astrocytoma Market

• 18.1. France Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anaplastic Astrocytoma Market

• 19.1. Italy Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anaplastic Astrocytoma Market

• 20.1. Spain Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anaplastic Astrocytoma Market

• 21.1. Eastern Europe Anaplastic Astrocytoma Market Overview
• 21.2. Eastern Europe Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anaplastic Astrocytoma Market

• 22.1. Russia Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anaplastic Astrocytoma Market

• 23.1. North America Anaplastic Astrocytoma Market Overview
• 23.2. North America Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anaplastic Astrocytoma Market

• 24.1. USA Anaplastic Astrocytoma Market Overview
• 24.2. USA Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anaplastic Astrocytoma Market

• 25.1. Canada Anaplastic Astrocytoma Market Overview
• 25.2. Canada Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anaplastic Astrocytoma Market

• 26.1. South America Anaplastic Astrocytoma Market Overview
• 26.2. South America Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anaplastic Astrocytoma Market

• 27.1. Brazil Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anaplastic Astrocytoma Market

• 28.1. Middle East Anaplastic Astrocytoma Market Overview
• 28.2. Middle East Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anaplastic Astrocytoma Market

• 29.1. Africa Anaplastic Astrocytoma Market Overview
• 29.2. Africa Anaplastic Astrocytoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Anaplastic Astrocytoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Anaplastic Astrocytoma Market, Segmentation By Treatment Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anaplastic Astrocytoma Market Competitive Landscape And Company Profiles

• 30.1. Anaplastic Astrocytoma Market Competitive Landscape
• 30.2. Anaplastic Astrocytoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Anaplastic Astrocytoma Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Mylan N.V.
• 31.3. Eisai Co. Ltd
• 31.4. Boehringer Ingelheim International GmbH
• 31.5. Perrigo Company Plc
• 31.6. Ipsen SA
• 31.7. Genentech Inc
• 31.8. Cipla Limited
• 31.9. Novocure Ltd.
• 31.10. Celon Laboratories Limited
• 31.11. Avid Bioservices Inc.
• 31.12. EirGen Pharma Ltd.
• 31.13. Monteris Medical Corporation
• 31.14. GLS Pharma Pvt. Ltd.
• 31.15. Tocagen Inc.

32. Global Anaplastic Astrocytoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anaplastic Astrocytoma Market

34. Recent Developments In The Anaplastic Astrocytoma Market

35. Anaplastic Astrocytoma Market High Potential Countries, Segments and Strategies

• 35.1 Anaplastic Astrocytoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Anaplastic Astrocytoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Anaplastic Astrocytoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer